Antibodies
13 March 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis13 March 2007
TopoTarget Executes Its Licensing Option for the Development of Zemab for Breast Cancer8 March 2007
MAT Biopharma Announced Today the Initiation of the Phase I/II Escalating Dose of Ferritarg P(R)28 February 2007
Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate Cancer28 February 2007
Vaccinex Announces Antibody Development And Commercialization Alliance In Multiple Sclerosis And Oncology28 February 2007
EvoGenix and Vegenics announce collaboration27 February 2007
Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan24 February 2007
Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer23 February 2007
New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer15 February 2007
Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection15 February 2007
DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platform14 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosusNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports